DK1801108T3 - Morpholinforbindelser til behandling af inflammationer. - Google Patents

Morpholinforbindelser til behandling af inflammationer.

Info

Publication number
DK1801108T3
DK1801108T3 DK05783689.2T DK05783689T DK1801108T3 DK 1801108 T3 DK1801108 T3 DK 1801108T3 DK 05783689 T DK05783689 T DK 05783689T DK 1801108 T3 DK1801108 T3 DK 1801108T3
Authority
DK
Denmark
Prior art keywords
inflammation
treatment
morpholine compounds
morpholine
compounds
Prior art date
Application number
DK05783689.2T
Other languages
Danish (da)
English (en)
Inventor
Yoshihito Tanaka
Shuzo Takeda
Hidemitsu Higashi
Mamoru Matsuura
Fujio Kobayashi
Maiko Hamada
Minoru Tanaka
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DK1801108T3 publication Critical patent/DK1801108T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK05783689.2T 2004-09-08 2005-09-08 Morpholinforbindelser til behandling af inflammationer. DK1801108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004261655 2004-09-08
PCT/JP2005/017002 WO2006028284A1 (ja) 2004-09-08 2005-09-08 モルホリン化合物

Publications (1)

Publication Number Publication Date
DK1801108T3 true DK1801108T3 (da) 2013-02-18

Family

ID=36036551

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05783689.2T DK1801108T3 (da) 2004-09-08 2005-09-08 Morpholinforbindelser til behandling af inflammationer.

Country Status (13)

Country Link
US (1) US7935700B2 (enExample)
EP (1) EP1801108B9 (enExample)
JP (1) JP4970946B2 (enExample)
KR (1) KR101011848B1 (enExample)
CN (1) CN101014580B (enExample)
CA (1) CA2579207C (enExample)
DK (1) DK1801108T3 (enExample)
ES (1) ES2396419T3 (enExample)
IN (1) IN2014CN03493A (enExample)
PL (1) PL1801108T3 (enExample)
PT (1) PT1801108E (enExample)
TW (1) TW200619212A (enExample)
WO (1) WO2006028284A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398616T1 (de) * 2005-02-04 2008-07-15 Ctg Pharma S R L Neue 4-aminochinolinderivate als antimalariamittel
RS52711B (sr) 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US8030303B2 (en) 2006-07-11 2011-10-04 Mitsubishi Tanabe Pharma Corporation Salt of morpholine compound
WO2008036642A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP5313881B2 (ja) 2007-04-04 2013-10-09 興和株式会社 テトラヒドロイソキノリン化合物
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
US10130634B2 (en) 2013-07-24 2018-11-20 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for ophthalmic disease
KR102617531B1 (ko) 2013-11-08 2023-12-27 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제 억제제의 합성 방법
WO2020203822A1 (ja) * 2019-03-29 2020-10-08 千寿製薬株式会社 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
US12472166B2 (en) 2019-08-26 2025-11-18 Stichting Vumc Inhibition of mycobacterial type VII secretion
EP4076448A4 (en) 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264467A (ja) 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH03148276A (ja) * 1989-11-01 1991-06-25 Yoshitomi Pharmaceut Ind Ltd 光学活性なピリドンカルボン酸化合物
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP0920306A2 (en) 1996-07-12 1999-06-09 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
CA2329821A1 (en) 1998-04-27 1999-11-04 Dashyant Dhanak Ccr-3 receptor antagonists
EP1076557A1 (en) 1998-04-27 2001-02-21 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000031033A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
CA2319435A1 (en) 1998-12-04 2000-06-15 Toray Industries, Inc. Triazolo derivatives and chemokine inhibitors containing the same as effective component
AU2942000A (en) * 1999-03-11 2000-09-28 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
CA2423305A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
CA2423251A1 (en) * 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002088111A1 (en) 2001-04-27 2002-11-07 Mitsubishi Pharma Corporation Novel benzylpiperidine compound
GB0207445D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0208158D0 (en) 2002-03-28 2002-05-22 Glaxo Group Ltd Novel compounds
GB0207443D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB0212355D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
CA2490148A1 (en) * 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix

Also Published As

Publication number Publication date
KR101011848B1 (ko) 2011-02-01
PT1801108E (pt) 2012-12-03
CN101014580A (zh) 2007-08-08
JP4970946B2 (ja) 2012-07-11
KR20070099528A (ko) 2007-10-09
EP1801108B9 (en) 2013-11-20
US7935700B2 (en) 2011-05-03
WO2006028284A1 (ja) 2006-03-16
TW200619212A (en) 2006-06-16
TWI367209B (enExample) 2012-07-01
CA2579207C (en) 2011-10-18
EP1801108A4 (en) 2010-10-13
EP1801108B1 (en) 2012-11-14
EP1801108A1 (en) 2007-06-27
JPWO2006028284A1 (ja) 2008-05-08
PL1801108T3 (pl) 2013-04-30
US20070265257A1 (en) 2007-11-15
ES2396419T3 (es) 2013-02-21
IN2014CN03493A (enExample) 2015-07-03
CA2579207A1 (en) 2006-03-16
CN101014580B (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
NL1029015A1 (nl) Therapeutische verbindingen.
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
CY2200156T2 (el) Επεξεργασια λυματων
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
NL1030382A1 (nl) Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen.
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1709082T3 (da) Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK3326681T3 (da) Indretning til behandling af analsphincteren
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1789529T3 (da) Fremgangsmåde til forbedring af konserveringen af lactococcus
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi